Safelia® autoinjector is selected as finalist for the ‘Excellence in Pharma: Drug Delivery Devices’ CPhI Pharma AwardsSeptember 30, 2016
Nemera has been selected as finalist at CPhI Awards for the ‘Excellence in Pharma: Drug Delivery Devices” category for Safelia®, its new generation of 2-steps autoinjector for fluid and viscous formulations.
Safelia® is an innovative autoinjector, declined in 1ml and 2.25m platforms for prefilled syringes, able to administer high volumes, high viscosities and through thinner needles.
It has been designed to ease patient self-injection experience and to deliver, in glass syringes, fluid formulations to challenging drugs (viscous, sustain released, concentrated, in subcutaneous or intramuscular layers, in large volumes…).
Key benefits of Safelia®
- No initial injection peak
- Constant delivery flow
- Adjustable needle insertion speed
- Needle insertion disconnected from injection
- Automatic needle retraction
- Possibility to have thinner needles
- Syringe is held encapsulated through the barrel
- Syringe front housing
- No stress on the syringe flange
- Possibility to inject very viscous drugs
You can discover Safelia® during CPhI Worldwide (booth 2M38), which is taking place in Barcelona, on October 4th-6th.
Nemera is a world leader in the design, development and manufacturing of drug delivery solutions. Its expertise covers several modes of delivery: Parenteral (autoinjectors, pens, and safety devices), Nasal/Buccal/Auricular (spray pumps, actuators, valves, etc.), Ophthalmic (preservative-free multidose eyedroppers), Pulmonary (pMDI, MDI’s, DPI’s) and Dermal /Transdermal (airless & atmospheric dispensers).
Nemera provides solutions for the pharmaceutical industry, including standard innovative products, the development of proprietary devices and contract manufacturing.